Loading
Lung Cancer Research Studies / Lung Cancer Treatments and Mutations · Journal article
Frontiers in Immunology · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a single case report of a 74-year-old male with extensive-stage SCLC and intracranial recurrence after palliative WBRT who received tislelizumab plus chemotherapy (irinotecan and cisplatin) followed by anlotinib maintenance, achieving complete response and 67-month overall survival. The source itself states that the clinical utility of this regimen requires validation in prospective controlled trials, and the evidence is insufficient to support practice change.
Case report and literature review. A 74-year-old Chinese male with extensive-stage SCLC presenting with synchronous hepatic metastases and later developing intracranial recurrence after palliative whole-brain radiotherapy.. Intervention: Second-line therapy comprising tislelizumab in combination with irinotecan and cisplatin chemotherapy, followed by anlotinib maintenance therapy.. n = 1.
Single patient achieved complete response with sustained no evidence of disease for 24 months Overall survival of 67 months from initial diagnosis in ES-SCLC with intracranial recurrence Brain metastases developed 19 months after thoracic radiotherapy; intracranial recurrence observed 5 months after palliative WBRT
No information on adverse events, tolerability, or mechanism of response.
This case suggests a potential therapeutic strategy for a difficult clinical scenario (intracranial recurrence post-WBRT in ES-SCLC) but cannot guide practice without controlled evidence. Clinicians should view this as hypothesis-generating and await prospective trials before adopting this specific regimen outside research contexts.
A single case report with a favorable outcome raises a mechanistic question about drug combination efficacy but provides no comparative evidence, control group, or generalizable data to support clinical practice change.
As stated by the source record.
Quoted from the source exactly as published.
This case suggests a potential therapeutic strategy for a difficult clinical scenario (intracranial recurrence post-WBRT in ES-SCLC) but cannot guide practice without controlled evidence. Clinicians should view this as hypothesis-generating and await prospective trials before adopting this specific regimen outside research contexts.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases. It is characterized by an exceptionally high proliferative rate, a strong propensity for early metastasis, and a poor prognosis. The median overall survival (OS) following brain metastases development in extensive-stage SCLC (ES-SCLC) was 10.5 months. Herein, a 74-year-old Chinese male was initially diagnosed with ES-SCLC with synchronous hepatic metastases. Following four cycles of first-line chemotherapy comprising etoposide and carboplatin, the patient underwent thoracic radiotherapy (TRT); however, prophylactic cranial irradiation was not performed. Brain metastases were detected 19 months after TRT, prompting initiation of palliative whole-brain RT (WBRT). Intracranial disease recurrence was observed five months after completion of WBRT. Managing intracranial recurrence following palliative WBRT in patients with ES-SCLC is clinically challenging. In this case of intracranial recurrence following palliative WBRT, the patient received second-line therapy comprising tislelizumab in combination with irinotecan and cisplatin chemotherapy, followed by anlotinib as maintenance therapy, achieving a complete response, sustained status of no evidence of disease for 24 months, and an OS of 67 months. Based on this case, tislelizumab combined with chemotherapy followed by anlotinib maintenance therapy represents a potentially viable treatment strategy for patients with recurrent intracranial lesions following palliative WBRT who have not received prior immune checkpoint inhibitor therapy. However, given the limited evidence derived solely from a single case, the clinical utility of this regimen requires validation in prospective and controlled trials.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.